Better Therapeutics: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Better Therapeutics (NASDAQ:BTTX) reported its Q3 earnings, beating estimated earnings by 28.57% with an EPS of $-0.15 versus an estimate of $-0.21. However, revenue was down $0 from the same period last year. Last quarter, a beat on EPS was followed by a 1.62% drop in the share price the next day.
November 09, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Better Therapeutics beat Q3 earnings estimates but saw no change in revenue from last year. Past performance suggests a potential drop in share price.
Better Therapeutics beat earnings estimates, which is generally a positive signal. However, the company's revenue was unchanged from last year, indicating a potential stagnation in growth. Additionally, past performance shows that a beat on earnings was followed by a drop in share price, suggesting a potential negative short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100